Text Size

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

This study has been completed.
Sponsor:
Collaborator:
Vietnam National University
Information provided by (Responsible Party):
Vuong Thi Ngoc Lan, Ho Chi Minh City University of Medicine and Pharmacy
ClinicalTrials.gov Identifier:
NCT01493440
First received: December 14, 2011
Last updated: December 16, 2011
Last verified: December 2011
History of Changes
  Purpose

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).


Condition Intervention
Repeated Implantation Failure
 Drug: atosiban

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by An Sinh Hospital:

Primary Outcome Measures:
  • Clinical pregnancy [ Time Frame: 5 weeks after intervention ] [ Designated as safety issue: No ]

Enrollment: 71
Study Start Date: March 2011
Study Completion Date: September 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Atosiban Drug: atosiban
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Other Name: Tractocile

Detailed Description:

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • had repeated implantation failure
  • have at least 1 good quality embryo for transfer

Exclusion Criteria:

  • uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01493440

Locations
Vietnam
IVFAS, An Sinh Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam, 8
Sponsors and Collaborators
An Sinh Hospital
Vietnam National University
Investigators
Principal Investigator: Lan TN Vuong, MD University of Medicine and Pharmacy of Ho Chi Minh City
  More Information

No publications provided

Responsible Party: Vuong Thi Ngoc Lan, Lecturer and Researcher, Department of Obstetrics and Gynecology, Ho Chi Minh City University of Medicine and Pharmacy
ClinicalTrials.gov Identifier: NCT01493440     History of Changes
Other Study ID Numbers: IVFAS1103
Study First Received: December 14, 2011
Last Updated: December 16, 2011
Health Authority: Vietnam: Ministry of Health

Keywords provided by An Sinh Hospital:
atosiban
clinical pregnancy
implantation rate
uterine contractility
IVF-ET

Additional relevant MeSH terms:
Atosiban
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
 Pharmacologic Actions
Tocolytic Agents
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 13, 2013